Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Galectin Therapeutics

26/03/2024 12:45

* Galectin Therapeutics Inc  GALT.OQ   GALT.O  is expected
to show
no change in quarterly revenue when it reports  results on March
28 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Galectin Therapeutics
Inc is
for a loss of 16 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00​, above​ its last closing price
of $2.33. ​​​

This summary was machine generated March 26 at 12:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)